These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34293490)

  • 61. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
    BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS.
    O'Donnell MR; Padayatchi N; Wolf A; Zelnick J; Daftary A; Orrell C; Nimmo C; Baldwin M; Boodhram R; Maharaj B; Amico KR; Naidoo K; Friedland G
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):325-332. PubMed ID: 35195572
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
    Zou J; Chen S; Rao W; Fu L; Zhang J; Liao Y; Zhang Y; Lv N; Deng G; Yang S; Lin L; Li L; Liu S; Qu J
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0081122. PubMed ID: 36106884
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE; D'Ambrosio L; Centis R; Tiberi S; Dheda K; Alffenaar JW; Amale R; Belilowski E; Bruchfeld J; Canneto B; Denholm J; Duarte R; Esmail A; Filippov A; Davies Forsman L; Gaga M; Ganatra S; Igorevna GA; Lazaro Mastrapa B; Manfrin V; Manga S; Maryandyshev A; Massard G; González Montaner P; Mullerpattan J; Palmero DJ; Pontarelli A; Papavasileiou A; Pontali E; Romero Leyet R; Spanevello A; Udwadia ZF; Viggiani P; Visca D; Sotgiu G; Migliori GB
    J Infect; 2019 Jan; 78(1):35-39. PubMed ID: 30096332
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases.
    Jones J; Mudaly V; Voget J; Naledi T; Maartens G; Cohen K
    BMC Infect Dis; 2019 Jun; 19(1):544. PubMed ID: 31221100
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
    Manalan K; Green N; Arnold A; Cooke GS; Dedicoat M; Lipman M; Loyse A; Harrison TS; Kon OM
    J Infect; 2020 Jan; 80(1):38-41. PubMed ID: 31550466
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.
    Patel H; Pawara R; Pawara K; Ahmed F; Shirkhedkar A; Surana S
    Tuberculosis (Edinb); 2019 Jul; 117():79-84. PubMed ID: 31378273
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis.
    Yao G; Zhu M; Nie Q; Chen N; Tu S; Zhou Y; Xiao F; Liu Y; Li X; Chen H
    J Int Med Res; 2023 Jan; 51(1):3000605221148416. PubMed ID: 36719280
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
    Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
    Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
    Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
    Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
    Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
    Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    Lan Z; Ahmad N; Baghaei P; Barkane L; Benedetti A; Brode SK; Brust JCM; Campbell JR; Chang VWL; Falzon D; Guglielmetti L; Isaakidis P; Kempker RR; Kipiani M; Kuksa L; Lange C; Laniado-Laborín R; Nahid P; Rodrigues D; Singla R; Udwadia ZF; Menzies D;
    Lancet Respir Med; 2020 Apr; 8(4):383-394. PubMed ID: 32192585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clofazimine in the treatment of multidrug-resistant tuberculosis.
    Xu HB; Jiang RH; Xiao HP
    Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.